Spearpoint

SpearPoint Analytics is a Swedish healthcare AI and diagnostics company focused on improving prostate cancer diagnosis and prognosis. The company develops AI-based pathology analysis tools that use microscopy images of tissue sections and outcome-based modeling to predict prostate cancer aggressiveness. Its lead platform, PCAI (Prostate Cancer Aggressiveness Index), is designed to support pathologists with a more objective second opinion and more reliable risk stratification than conventional grading alone. SpearPoint appears to be in the research and validation stage rather than commercial deployment, with work centered on multi-center validation and clinical robustness. The company combines machine learning, digital pathology, and clinical expertise, and has collaborated with academic and research institutions in Sweden and Germany.